Stocks and Investing Stocks and Investing
Thu, December 19, 2024
[ Thu, Dec 19th 2024 ] - Fortune
Motown: What's going on?
Wed, December 18, 2024
[ Wed, Dec 18th 2024 ] - rnz
NZ Sporting History: Anna Simcic
[ Wed, Dec 18th 2024 ] - knowledge.insead.edu
Decoding AI Adoption
[ Wed, Dec 18th 2024 ] - The New York Times
The New Politics
[ Wed, Dec 18th 2024 ] - Science Daily
Biodiversity News
[ Wed, Dec 18th 2024 ] - Travel + Leisure
The Best Resorts in Mexico

Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug


Published on 2024-12-18 16:21:24 - The Motley Fool
  Print publication without navigation

  • But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose weight. A recent study found that it may not be Ozempic or Wegovy that's the best weight loss drug. Instead, that could come from Novo Nordisk's longtime rival, Eli Lilly ( LLY -0.17%).

The article from The Motley Fool discusses a head-to-head study comparing Ozempic, a popular weight loss drug, with Mounjaro, another weight loss medication. The study, which was published in the Journal of the American Medical Association (JAMA), found that Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) in terms of weight loss efficacy. Participants on Mounjaro lost significantly more weight than those on Ozempic, with the study highlighting Mounjaro's dual mechanism of action targeting both GLP-1 and GIP receptors, potentially explaining its superior results. This news has implications for investors and patients, as Mounjaro's manufacturer, Eli Lilly, could see increased market share and revenue, while Novo Nordisk, the maker of Ozempic, might face competitive pressure. The article also touches on the broader market dynamics, including the potential for Mounjaro to become a preferred choice for weight management, affecting stock prices and future pharmaceutical developments in the obesity treatment sector.

Read the Full The Motley Fool Article at:
[ https://www.fool.com/investing/2024/12/18/ozempic-dethroned-a-head-to-head-study-confirms-th/ ]